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Abstract
CD36 is recognized as a lipid and fatty acid receptor and plays an important role in the metabolic syndrome and associated
cardiac events. The pleiotropic activity and the multiple molecular associations of this scavenger receptor with membrane
associated molecules in different cells and tissues have however questioned its potential as a therapeutic target. The
present study shows that it is possible to identify low molecular weight chemicals that can block the CD36 binding and
uptake functions. These inhibitors were able to reduce arterial lipid deposition, fatty acid intestinal transit, plasma
concentration of triglycerides and glucose, to improve insulin sensitivity, glucose tolerance and to reduce the plasma
concentration of HbAc1 in different and independent rodent models. Correlation between the anti-CD36 activity of these
inhibitors and the known pathophysiological activity of this scavenger receptor in the development of atherosclerosis and
diabetes were observed at pharmacological doses. Thus, CD36 might represent an attractive therapeutic target.
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Introduction
CD36 is a member of the scavenger receptor family with a
broad cell type expression. The specificity of this receptor for
oxidized lipoproteins (ox-LDL) is extensively documented [1–4].
This receptor is up regulated by ox-LDL in macrophages and
contributes to the formation and accumulation of foam cells at
sites of arterial lesions during early and late atherosclerosis. This
concept was validated by the finding that mice with double CD36
and ApoE deficiency exhibited a greater than 77% decrease in
aorta lesions and 50% decrease in aortic sinus lesions despite the
induction of a very high atherogenic milieu [5]. This phenomenon
was explained by the fact that recruitment and accumulation of
foam cells at sites of lesions were considerably reduced in animals
lacking CD36 [6,7]. Such a conclusion was however challenged by
the observation that combined deficiencies in scavenger A and
CD36 functions did not ameliorate atherosclerosis in hyperlipid-
emic mice [8].
The role of CD36 in the binding and transport of long chain
fatty acid (LCFA) in enterocytes and adipocytes is also well
documented [9–12]. The protein is involved in the control of the
intestinal transit of cholesterol, triglycerides (TG) and fatty acids
(FA) [13–15]. CD36 deficiency can also rescue lipotoxic cardio-
myopathy [16] and control hepatic triglycerides storage and
secretion [17]. Lipid binding to CD36, at the early stage of
intestinal lipid absorption, stimulates and controls chylomicron
secretion [14,15]. Thus, CD36 has a broad implication in FA
membrane transport and may possibly be involved in the
metabolic aspects of dyslipidaemia [17]. Observation that CD36
may regulate downstream signalling in enterocytes and stimulate
chylomicron synthesis supports this hypothesis [18]. This concept
is however questioned by the consistent observation that CD36
gene deletion does not affect plasma TG concentration, LCFA
uptake and TG re-esterification in mouse proximal intestine and
that postprandial plasma TG concentration is increased in CD36
deficient humans [18,19]. Therefore, the direct role of CD36 in
the intestinal absorption of FA and its pathological hyperlipemia
consequence remains an open question.
In addition to its potential implication in atherosclerosis and
dyslipidaemia, independent studies have suggested that CD36 may
also be directly or indirectly involved in diabetes [20,21]. CD36
deficient humans were reported to have insulin resistance [19,22].
CD36 gene knock out, however, did not induce insulin resistance
in mice [5]. Rather, insulin sensitivity was increased in CD36
2/2
skeletal muscle [23]. Furthermore, defective insulin signalling was
shown to be associated with increased CD36 expression in
macrophages [24]. In addition, ox-LDL produced a dramatic
reduction of Glyceraldehyde-3-phosphate deshydrogenase in
smooth muscle cells resulting in a marked reduction of glucose
usage [25]. Together, these observations suggest that CD36 is
inversely correlated with insulin sensitivity and plasma lipopro-
teins. In contrast, animals over expressing CD36 in muscle
exhibited decreased plasma concentrations of triglycerides and
increased plasma insulin and glucose concentrations [26] and
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animals [23]. Therefore, opinions concerning a direct or indirect
role of CD36 in insulin resistance and the development of type II
diabetes are diverging.
In summary, the preponderance of evidence suggests that CD36
is a central receptor for the detection, accumulation and
metabolism of lipids and fatty acids in different cells and tissues.
CD36 could then function as a molecular bridge between the
development of dyslipidaemia and insulin resistance [21]. If so, it
may represent an interesting therapeutic target for the treatment
of atherosclerosis, type II diabetes and obesity and their associated
cardiovascular diseases. In support with that hypothesis, we show
that small molecules with anti-CD36 activity can reduce
postprandial hyperlipidaemia and protect against type II diabetes
and atherosclerosis.
Materials and Methods
Cell Culture
HEK 293 cells (ATCC) were transfected with a full length
human CD36 cDNA to obtain a permanent CD36 expressing cell
line. Expression of a functional CD36 at the surface of the cells was
characterized by flow cytometry using monoclonal anti-CD36
antibody (FA6.152, Abcam). Human THP-1 cells (ECCAC) were
cultured in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS), 200 mmol/L L-Glutamine, 100 Unit/mL
penicillin and 100 mg/mL streptomycin. HEK 293 wt and
HEK293-CD36 cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS, 1 mmol/L
Sodium Pyruvate, 0.1 mmol/L non essential amino acids,
200 mmol/L L-Glutamine, 100 Unit/mL penicillin and 100 mg/
mL streptomycin. CD36 expressing cells were all time cultured in
presence of 300 mg/mL selection antibiotic G418 (sigma). For
THP1 experiments, cells were differentiated into macrophages in
RPMI-1640 medium supplemented with 5% FBS and 10
27 mol/
L of PMA for 24 hours at 37uC, 5% CO2. For experiments with
HEK293 and CD36 expressing HEK293, cells were plated in 96-
black plate coated with poly-D-lysine for 48 hours at 37uC, 5%
CO2 in DMEM containing 10% FBS.
Lipoproteins Preparation
LDL were prepared by discontinuous density gradient ultra-
centrifugation from normal human plasma provided by Etablisse-
ment Franc ¸ais du Sang. LDL were oxidized with 5 mmol/L
CuSO4 for 15 hours at 37uC. Oxidation was stopped by addition
of 40 mmol/L butylated hydroxitoluene (BHT) and 100 mmol/L
diethylene triamine penta acetic acid (DTPA), then extensively
dialyzed against phosphate buffered saline containing 100 mmol/L
DTPA. Oxidized-LDL were labeled with cyanine3 Mono NHS
ester. Oxidation was controlled by electrophoretic mobility and
the measurement of optical density at 234 nm corresponding to
the formation of conjugated dienes.
LCFA Preparation and Endocytosis Experiments
Fat-free BSA, Bodipy fl C16 (Molecular probes), palmitate and
Phloretin were purchased from commercial sources. Both the
albumin and palmitate concentration were 173 mmol/L.
23 mmol/L of the palmitate component were bodipy fl C16 and
150 mmol/L were non-fluorescent palmitate. Briefly, HEK293
and HEK293/CD36 cells were preincubated for 30 minutes at
37uC in serum free DMEM containing 0.1% dimethylsulfoxide
(DMSO) or molecules. Following preincubation, the culture
medium were replaced with phosphate buffer saline containing
BSA/palmitate/bodipy fl C16 complex in presence of 0.1%
DMSO or molecules. The uptake was stopped by removal of the
solution followed by addition of 100 mL of an ice-cold stop solution
containing 0.5% of free fatty acid albumin and 0.2 mmol/L of
Phloretin. The stop solution was discharged after 2 minutes and
the culture dishes were washed by deeping them three times in ice-
cold incubation buffer.
The cells were fixed in 4% paraformaldehyde during 30
minutes at 4uC and nucleus were stained by incubation in buffer
saline containing 1 mg/mL of Hoechst 33342 during 20 minutes at
room temperature. Then, cells were washed twice in phosphate
buffer saline. The Leica DMIRB microscope system was used for
staining visualization. 16 images by well of cells staining with
Bodipy fl C16 and Hoechst 33342 were automatically captured
using a fluorescence microscope controlled by MetaMorph
Software (Universal Imaging) and coupled with a CCD camera.
After images analysis, results were expressed as the sum of bodipy
intensity per cells number.
Ox-LDL Binding and Endocytosis Experiments
All binding experiments were performed at 4uC. HEK wt and
HEK-CD36 at 80% of confluence in 96-well plates were
incubated with the appropriate medium containing 1 mg/mL of
Hoechst 33342 for 20 minutes at 4uC. After washing twice, cells
were incubated in medium supplemented with 0.5% FBS and
cyanine 3-oxidized-LDL (20 or 35 mg/mL), in the absence or the
presence of increasing concentration of the compound for 4 hours
at 4uC. Cells were fixed with 4% paraformaldehyde for 15 minutes
at 4uC and then washed with phosphate buffered saline before
fluorescence microscopy analysis.
For endocytosis experiments, the cells, at 80% confluence, in 96
well plates, were incubated with the appropriate concentration of
the compound for required time at 37uC. Cells were fixed with 4%
paraformaldehyde for 20 minutes at room temperature. After
washing, the nucleus was labeled with 1 mg/mL of Hoechst 33342
for 20 minutes at room temperature.
Each stimulation condition for binding and endocytosis was
performed at 0.1% DMSO in quadruplicate. 16 images by well of
cells staining with Cyanine-3 and Hoechst 33342 were automat-
ically captured using a fluorescence microscope controlled by
MetaMorph Software (Universal Imaging) and coupled with a
CCD camera. After images analysis, results were expressed as the
sum of cyanine-3 intensity per cell number.
Animals and Experimental Protocols
All experiments were carried out according to the guidelines
laid down by the French Ministe `re de l’Agriculture and E.U.
Council Directive for the Care and Use of Laboratory Animals (Nu
02889). Experimental procedures in animals were performed in
accordance with protocols approved by the Institutional Animal
Care and Research Advisory Committee of KU Leuven
(LA1210544) and Comite ´ d’Expe ´rimentation Animale of Univer-
sity Claude Bernard, Lyon1 (BH 2012–23).
Rodent Models
Atherosclerosis mouse model. Homozygous LDL-receptor
deficient (LDL-R
2/2) mice, heterozygous leptin deficient mice
(ob/+) and C57BL/6 mice were purchased from Jackson
Laboratories. Double knockout mice (DKO) characterized by
both leptin deficiency (ob/ob) and LDL-R deficiency were
obtained by crossing as previously described [26]. The phenotypic
attributes of these DKO mice have been previously characterized
in details [26]. All mice were maintained in controlled conditions
(22uC with a fixed 12/12 hour light/dark cycle) and fed standard
chow containing 4% fat (Pavan Service). Mice were daily treated
CD36 Inhibitors
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1 mg/kg supplemented with 1% methyl cellulose or vehicle (10%
DMSO).
Diabetic rat model. Male Wistar Han rats (250–260 g,
Elevage Janvier, Le Genest St Isle, France) were used. The
fructose diet-inducing diabetic model was previously well de-
scribed. Briefly, adult rats were fed with a standard chow (A04,
UAR, Villemoisson, France) and given ad libidum 10% fructose
solution for 21 days. After a 3-week diet, diabetic rats were daily
treated by IP administration of different doses of the compound,
mixed with 2% DMSO or PEG 300 for 21 days. Plasma samples
were obtained in the fed state via the tail and prepared for
concentration measurements of TG levels.
Prediabetic ZDF rat model. Male Zucker diabetic fatty
rats (ZDF-Lepr fa/Crl) (5 weeks old) (Charles River, France)
were fed maintenance rodent diet 2016 C (Harlan France).
These rats become diabetic between 7 and 10 weeks. After an
adaptation period of 2 weeks, vehicle, being either PEG 300, or
CD36 inhibitor (50 mg/kg) were administrated, during the rise of
plasma glucose. Blood samples were obtained from tail vein and
plasma glucose and HbA1c were determined throughout the 3
week treatment. Glycated hemoglobin was measured using the
direct Enzymatic HbA1c Assay
TM (Diazime laboratories, CA,
US). A second experiment was carried out on older Zucker rats
(18 weeks), in which rats received IP injections of AP5258. Oral
glucose tolerance and insulin tolerance test were performed at
the end of the treatment period. Blood samples were obtained
from tail vein and concentrations of plasma glucose and
triglycerides were determined during the time course of the
treatment.
Postprandial analysis in Sprague Dawley (SD)
rats. Sprague-Dawley rats (SD, 225–250 g) (Charles River,
France) were fed a rodent maintenance global diet (2016C, Harlan
France). Postprandial plasma TG concentrations were determined
during 6 hours after an olive oil test. Briefly, the animals were
fasted overnight for 16 hr and then forced fed with 1 mL of olive
oil. Blood samples were collected every hour through the tail vein.
Rats received either vehicle or active compound (50 mg/kg) in
Figure 1. Chemical structures and activities of the CD36 inhibitors AP 5055, AP 5258 and the negative analog AP5156. Dose
dependent inhibition of ox-LDL uptake and accumulation by THP1 cells at 37uC. Uptake was measured as the cyanin3 labeled ox-LDL uptake at
constant cell number.
doi:10.1371/journal.pone.0037633.g001
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PAP 150, Biome ´rieux, France.
Quantification of Atherosclerotic Plaque Lesions
After 12 weeks treatment with AP5055, the extent of
atherosclerosis was evaluated by serial cross sections from aortic
root. Immunohistochemical and morphometric analysis were
performed on 7-mm cryosections. Lipid staining with oil red O,
with mAb4E6, smooth muscle cells with an a-actin specific
antibody (Dako) and macrophages with an antibody against mouse
Mac-3 antigen (Pharmingen) were performed. Immunostained
sections were blindly analyzed with Quantimet 600 image
analyzer (Leika).
Oral Glucose Tolerance Test (OGTT)
Rats were fasted for 16 h before glucose solution (2 g/kg body
weight) was administered orally. Blood was drawn from a tail vein
at 10, 20, 30, 60, 90 and 120 min after the administration of
glucose. Plasma glucose concentration was measured with a
commercial glucometer (Accu-Chek, Roche, France).
Statistical Analysis
All data are reported as mean 6 standard error of the mean.
Plasma concentration assays were performed on 8 to 12 animals
per group. Statistical significance between control treated animals
was determined by analysis of variance (ANOVA). The Fisher
protected least significant difference, post hoc test was used for
group comparisons. Statistical significance was set at p,0.05.
Results
Identification and Characterization of Anti CD36
Inhibitors
To identify chemical compounds with anti-CD36 function, a
CD36-expressing HEK-293 cell line was established for high
throughput screening of large chemical libraries. One series of
pharmacophore was identified and optimized for their capacity to
inhibit binding, uptake and accumulation of ox-LDL by THP1
cells. Two members of this series, named AP5055 and AP5258
produced a significant inhibition of foam cells formation with IC50
of 100 nM and 500 nM respectively and were selected for further
studies. This inhibition was observed at constant nucleus number
Figure 2. Anti-CD36 activity of AP5055 (dark) and AP5258 (grey) on CD36-HEK cells. Non transfected cells (wt), were used as control: A:
ox-LDL uptake at 37uC, B: Palmitate uptake at 37uC, C: typical inhibition of ox-LDL binding at 4uC, D: dose dependent inhibition of AP 5055 and
AP5258 on ox-LDL binding, AP5156 used as negative control had no effect (hatched bar), E: Comparative inhibition of ox-LDL binding by AP5055 and
AP5258 at different ox-LDL concentrations.
doi:10.1371/journal.pone.0037633.g002
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chemical structure was inactive indicating the presence of a
structure-function relationship within this chemical series.
HEK-CD36 cells interacted with both LCFA and oxidized
lipoprotein particles, stored these particles and accumulated lipid
rich vesicles in a CD36-dependent way. This cell line was further
utilized to explore the anti-CD36 activity of these chemical
entities. When performed at 37uC, lipid vesicles accumulation by
these cells was significantly inhibited by both AP5055 and AP5258
with IC50 similar to that observed with THP1 cells (Figure 2A).
Similarly, both AP5055 and AP5258 inhibited palmitate cellular
transfer to a level comparable to that observed with non-
transfected wild type cells (Figure 2B). Both inhibitors produced
a dose dependent inhibition of CD36-dependent binding to the
membrane of these cells with IC50 of 160.1 mM and 561 mM
respectively (Figure 2C and 2D). The analog AP5156 used as a
negative control, had no effect on this binding, up to a
concentration of 10
24 M (Figure 2D).
The compounds AP5055 and AP5258 were then utilized to
further explore the receptor inhibitor activity of this chemical
series. Different experiments indicated that these inhibitors are
receptor rather than oxLDL directed. First, the compounds did
not affect the electrophoretic mobility of the complex at any
concentration tested as illustrated in Figure 3A. Second, both
AP5055 and AP5258 had no effect on the CD36-independent
binding as observed with wild type HEK cells. This level of CD36-
independent binding never exceeded 15% on the wt HEK cells.
Third, when bound biotynilated-oxLDL was affinity cross-linked
to the HEK-CD36 membrane, then immunoprecipitated with an
anti-biotin monoclonal antibody, and analyzed by western blotting
with an anti-CD36 monoclonal antibody, after reduction to
quantify bound receptors, the compound produced a significant
inhibition of the oxLDL-CD36 complex cross-linking. Figure 3B
exemplifies the results obtained with AP5055. AP5258 had a
similar effect. Non transfected wt HEK cells did not crosslink
oxLDL. Finally, compound-induced inhibition was dependent
upon the concentration of the ligand, with an increased inhibitory
capacity at greater ox-LDL concentration suggesting that AP5055
and AP5258 are noncompetitive CD36 inhibitors (Figure 2 E).
Altogether, these experiments demonstrated that both molecules
were inhibitors of the oxLDL and LCFA receptor functions of
CD36 with AP5055 being slightly more potent than AP5258.
Protection Against Atherosclerosis
CD36 deficient mice are protected against atherosclerosis.
Therefore, the in vivo efficacy of the compound to protect against
atherosclerosis was first examined in double LDL-R and leptin
deficient mice (DKO). Figure 4 illustrates the results and
exemplifies the activity obtained when AP5055 was administrated
to these mice. Typical oil red O-staining of the lesions in the aortic
root of treated free fed mice (24 weeks old) was compared to non-
treated animals. Consistent with previously published observations
Figure 3. Anti-CD36 activity. Effect of AP5055 on the molecular interaction between CD36 and ox-LDL using CD36-HEK and wild type (wt) cells at
4uC. A: effect on the electrophoretic mobility of ox-LDL, B: Affinity crosslinking of ox-LDL to membrane expressed CD36, biotinylated ox-LDL were
cross linked at 4uC, the ox-LDL complex was immunoprecipitated with an anti ox-LDL antibody and complex-associated CD36 was detected on
immunoblot, using an anti CD36 antibody.
doi:10.1371/journal.pone.0037633.g003
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volumes at 0.08460.034 mm
3 (n=19). Daily IP injection of the
compound at 1 mg/kg for a period of 12 weeks produced a
significant reduction of lipid deposition as illustrated by the
reduction of oil red O staining. Plaque volume was reduced to
0.04560.032 mm
3 (n=12) corresponding to a 46% reduction.
Concomitant with the reduction of lipid deposition, a significant
decrease of plasma TG was observed (Figure 4B). TG did not
change in placebo treated mice while AP5055 produced a greater
than 50% reduction. Thus, anti-CD36 compounds are able to
protect against the growth of atherosclerotic plaque at an in vivo
concentration compatible with the in vitro activity of this molecule
(,10
25 M). Reduction of the plasma level of TG was however
unexpected because CD36-deficient mice were reported to have
increased levels of plasma TG (Figure 4C).
To verify that this result was not model specific and was not due
to the double knock-out of both the LDL-R and leptin genes in the
DKO mouse model, the effect of anti-CD36 molecule on plasma
TG concentration was examined in an independent diabetic
fructose fed rat model. Results that summarize these experiments
are illustrated in Figure 5. When administrated (IP) at concentra-
tion ranging from 0.1 to 10 mg/kg AP5055 was able to produce a
similar dose dependent reduction of the plasma TG within weeks
of treatment. When using the ZDF rat model, AP5258 produced a
significant reduction of the TG plasma concentration (Figure 5).
The inactive analog AP5156 had no effect (result not shown).
Therefore, the decrease in plasma TG correlated with the cellular
Figure 4. Protection against atherosclerosis. Effect of AP 5055 on the development of atherosclerosis in double LDL-R and Leptin deficient mice
(DKO). A: lipid deposition in the aorta, B: plaque volume, C: plasma TG concentration.
doi:10.1371/journal.pone.0037633.g004
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dependent. Differences in the potency of these molecules in the
different models were however observed. This may be explained
by the relative stringency of the different models in terms of
metabolic syndrome, the ZDF rat being less sensitive to the
treatment than the mouse or the fructose fed rat model.
Alternatively, the two compounds may have different metabolism.
Protection Against Insulin Resistance
When administrated to the DKO mice at 1 mg/kg, AP5055
produced a significant reduction of the plasma glucose and
improved glucose tolerance (Figure 6A).
To verify that this effect was not model dependent, AP5055 and
AP5258 were administrated to the ZDF rat model to measure
changes in fasting and non fasting plasma glucose. Typical results
are illustrated in the figure 6B and 6C. Both molecules were able
to reduce fasting and dietary plasma glucose levels after 3 w of
treatment at 40 mg/kg. Greater than 50% inhibition of plasma
glucose was obtained with AP5055 (434611 vs 196642 mg/dL),
whereas AP5258 produced a 20% inhibition at the same dose
(517623 vs 41367 mg/dL). AP5258 produced a similar correc-
tion on the oral glucose tolerance test. In addition to the induction
of a better glucose tolerance, sensitivity to insulin was also
improved. Typical results obtained for AP5258 are illustrated in
Figures 7A and 7B.
Therefore anti-CD36 inhibitors were able to improve glucose
tolerance in rodent animals with typical metabolic syndrome. The
effect on glucose tolerance was objectivized by the decrease of
HbAc1 observed on Zucker rat model (Figures 7C and 7D).
Reduction of Post Prandial Hyperlipidemia
The time course of the plasma TG response to a gastric olive oil
challenge is shown in Figure 8. After overnight fasting the plasma
TG concentrations were similar at time 0 in the control and
treated animals at an average level of 1.1660.35 mM. The
postprandial lipemia started to increase at 4 h in the non-treated
animals and reached a maximum value at 6 h. When the animals
were treated with AP5258 at 50 mg/kg the postprandial increase
of plasma triglycerides was inhibited. This total inhibition of the
intestinal transit was dose dependent since at a dose of 10 mg/kg
an intermediate effect was observed (Figure 8B).
These results were consistently reproduced in different and
independent series of animals. When taken at 4 hours, on a larger
number of animals (n=8), 50 mg/kg produced a greater than
40% inhibition (Table 1).
Discussion
In the present study, correlation between the anti-CD36
inhibitor activity of small molecular weight chemicals and the
known pathophysiological activity of this scavenger receptor were
established. Although different mechanisms may be involved in the
oral versus IP activity of these inhibitors, both administrations
were able to improve the metabolic profile of defined and
independent rodent models. A significant reduction of the plasma
concentration of triglycerides and a better glucose usage were
observed at pharmacological doses with a concomitant reduction
of the atherosclerotic and diabetic consequences of these
attributes.
CD36 is a well characterized FA translocase and an oxidized
LDL receptor expressed in many cell types including macrophag-
es, adipocytes, endothelial cells and enterocytes [3,9,10,14,27,28–
30]. Expression of this gene is ligand-binding dependent and can
either be up or down regulated. For instance, ox-LDL-CD36
interaction up regulates a PPARc-dependent CD36 gene expres-
sion in monocytes-macrophages [31] whereas interaction with FA
down regulates gene expression and protein synthesis in
enterocytes [18], but can up regulate the gene in adipocytes
[28]. In addition, CD36 may or may not be associated with
companion molecules. The Vitronectin receptor VNR [32–33],
caveolin-1 [34], the Intestinal alkaline phosphatase IAP [35], the
Figure 5. Reduction of plasma triglycerides. Comparative effect of CD36 inhibitors on the plasma concentrations of TG in different rat models,
A: Dose dependent reduction in a fructose fed rat, AP5055 was administrated at different doses for 3 w (n=12), B: AP5258 was administrated to
diabetic ZDF rats (C=Control, T=Treated) for a period of 2w at 10 mg/kg (n=8).
doi:10.1371/journal.pone.0037633.g005
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molecular and functional associations with CD36 at the surface of
cells. Therefore, genetic expression and molecular functions of
CD36 are complex and controlled by membrane and tissue
specific molecular associations and different cellular specific
signaling pathways. This pleiotropic effect may reasonably well
question the clinical relevance and safety of CD36.
While the cellular functions of CD36 are recognized, its
importance in the physiopathology is less well understood and
often controversial. The role of CD36 in the formation of foam
cells and the growth of atherosclerotic plaques is well documented.
Yet the role of CD36 as a target to combat atherosclerosis was
criticized [8]. Similarly, evidences supporting a role of CD36 in
intestinal fat absorption are accumulated, but contradictory
observations have also been reported concerning its direct
implication in intestinal lipid trafficking and the control of
postprandial hypertriglyceridemia. For instance, CD36 is ex-
pressed all through the intestinal tract and is important for the
metabolism and the secretion of chylomicron into the lymph [15].
The molecule is required for efficient intestinal absorption of
LCFA and VLCFA [13–15]. Yet, CD36 deficient mice exhibit a
normal level of FA absorption [15] and gene deletion does not
affect LCFA uptake and TG re-esterification in mouse jejunum
[18]. Therefore the potential of CD36 as a therapeutic target is
debated. In the present paper we have identified small chemical
molecules which have the capacity to inhibit the FA and ox-LDL
receptor function of CD36. These inhibitors were able to rescue
well characterized animal models from postprandial hypertriglyc-
eridemia and atherosclerosis with a concomitant improvement of
insulin resistance and glucose tolerance.
The CD36-inhibitor activity of this new chemical series was
established on the following criteria. First, the molecules were
Figure 6. Effect of CD36 inhibitors on insulin resistance. A: Effect of AP5055 (1 mg/kg), on the glucose level and the glucose tolerance in the
DKO mice, B: effect of AP5055 and AP 5258 on the plasma glucose in a ZDF rat (40 mg/kg, 3 w, n=8).
doi:10.1371/journal.pone.0037633.g006
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accumulation in THP1 cells. Furthermore, using CD36-transfect-
ed HEK cells the specificity of this inhibition for CD36 was
demonstrated. Active members of this series were able to
completely inhibit binding and uptake to levels that were similar
to the non-specific binding and uptake observed with wt cells.
Figure 7. Effect of CD36 inhibitor on the metabolic syndrome parameters. A: effect of AP5258 on OGT, B: Effect of 5258 on insulin
sensitivity, C: Effect of AP5055 on plasma glucose, D: Effect of 5055 on the plasma concentration of HbAc1.
doi:10.1371/journal.pone.0037633.g007
Figure 8. Reduction of FA intestinal transit. Oral administration of anti-CD36 inhibitor reduces post prandial HTTG following a gastric olive oil
challenge. A: kinetics of the TG intestinal transit in the plasma in control animals or treated animals (AP5258, 50 mg/kg n=12), B: Dose dependent
effect on Plasma TG (n=3).
doi:10.1371/journal.pone.0037633.g008
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for two different ligands, and the non-competitive agonist activity
of these inhibitors, a similar activity on LCFA binding and uptake
on both THP1 and HEK-CD36 cells was measured. These results
support a receptor rather than a ligand-driven inhibition. Third,
analogs of the same series with close chemical structure had no
effect on these cellular functions, suggesting the existence of a
structure-function relationship within the members of the series.
Finally, cross-linking affinity was used to demonstrate the effect of
the compounds on the molecular interaction between ox-LDL and
CD36. In aggregate, these new molecules were able to inhibit the
CD36 receptor function both at the cellular and the molecular
levels.
The first CD36 in vivo activity to be examined was its implication
in the development of atherosclerosis using a well characterized
animal model. A DKO mouse combining LDL-R and leptin
deficiencies was used. This model exhibits high blood pressure
together with increased plasma TG concentration, insulin and
glucose. It develops atherosclerosis and represents a good model to
study the physiopathology of the metabolic syndrome [26]. The
CD36-antagonists used in the present study were able to reduce
the growth of atherosclerotic plaques at plasma concentrations
compatible with the cellular activity of these molecules. This is in
agreement with the fact that CD36 depleted mice are protected
against atherosclerosis [5]. Unexpectedly, a significant reduction of
the plasma TG was also observed. Increased plasma TG
concentration is an important factor for the development of
atherosclerosis. The DKO mouse, the ZDF rat, and the fructose
rat model exhibited a significant increase of the plasma TG
concentration and in these animals, the compounds were able to
reduce plasma TG, indicating that this reduction was not model
dependent. These observations do not agree with previously
published observations showing that CD36 deletion in mice
impairs lipoprotein lipase-mediated TG clearance [39] and results
in increased levels of plasma triglycerides. The present study
demonstrates that an anti-CD36-ox-LDL and Fatty Acid binding
activity has the capacity to reduce plasma triglycerides in rodent
species. This reduction was in good agreement with the observed
reduction of lipoprotein deposition in the aortic tree and the
plaque growth. CD36 is implicated in lipid metabolism but has not
yet been implicated in lipogenesis. Therefore it is unlikely that an
inhibitor of CD36-binding may directly influence TG synthesis per
se. While a pleiotropic activity of these new chemicals cannot be
entirely excluded at the present time, the reason for this
discrepancy could be multiple. In the present study, the mouse
model was on a diet program for 12 week whereas in Febbraio’s
studies, the CD36 null mice were fasted for 24 hour. Other
differences may include gender and strain origin and differences in
lipid metabolism. For instance, in the double CD36-ApoE knock-
out mice, plasma TG were significantly different in male and
female mice, depending on the diet [5]. In the present study we
show that TG reduction was not affected by gender and genetic
deletion. Alternatively, differences between a total disruption of
the gene and a partial inhibition of the CD36 function with an IP
administration of an inhibitor can be expected. For instance,
CD36 expression in mice liver is low but the partial inhibitory
activity of an administrated antagonist may be sufficient to reduce
hepatic TG secretion [17]. The published observation that
heterozygotes with partial CD36 deficiency have reduced plasma
TG is in agreement with our findings and supports this possibility
[40].
Increased plasma levels of TG and atherosclerosis are generally
associated with impaired insulin action and glucose tolerance.
Epidemiologic studies have implicated insulin resistance in both
diabetes and coronary atherosclerosis [41–44]. Diabetic patients
have areas of lipid rich plaques with greater macrophage
infiltration and many of the processes that are implicated in
plaque progression are amplified by the diabetic parameters. But,
the molecular links between diabetes and atherosclerosis are still
missing. Glycaemia alone stimulates macrophage accumulation
but fails to promote macrophage proliferation at sites of lesions
[45]. Defective insulin signaling is associated with the expression of
CD36 and is enhanced via a CD36-dependent pathway [46,47].
Increased CD36 expression has been shown to contribute to
dyslipidemia and to be associated with insulin resistance and
decreased glucose tolerance, suggesting that CD36 is involved in
the physiopathology of insulin sensitivity. The present study
supports this concept and shows that administration of small
inhibitors of the CD36 functions improves insulin sensitivity and
glucose tolerance in rodent animals. This activity was not animal
model dependent and was not affected by genetic modifications.
Therefore, anti-CD36 therapy may be beneficial to both
atherogenic dyslipidemia and diabetes type2.
CD36 is expressed in both human and rat enterocytes and has
been shown to be involved in the control of intestinal cholesterol
and fatty acid uptake and secretion. CD36 is expressed in the small
intestine and plays an important role in chylomicron metabolism
and the production of large postprandial triglyceride rich particles
[14,48, and 18]. The molecule is associated with the intestinal
alkaline phosphatase in FA transport and the response to a fat diet
[48] and specific defect in FA uptake in the proximal intestine of
CD36
2/2 mice is associated with reduced incorporation of FA in
TG and a diminished TG secretion [14]. This concept was
however challenged. Published observations have shown that
CD36 genetic deletion does not affect intestinal lipid uptake and
the efficient participation of CD36 in LCFA intestinal uptake was
questioned [13,18]. It was suggested that CD36 functions as a FA
sensor and stimulates events that control FA metabolism rather
than being directly involved in the lipid transit. In any case, our
findings show that small inhibitors of the CD36 binding functions
can significantly reduce the postprandial hypertriglyceridemia
which follows a gastric olive challenge. Again, when compared to a
complete deletion of the gene, which favor redundant mecha-
nisms, a partial inhibition of CD36 functions may have different
consequences. Our findings demonstrate that a selective down
regulation of CD36 in the intestine reduces lipid intake and is
beneficial to postprandial hypertriglyceridemia.
In conclusion, CD36 is generally recognized as an important
lipid and FA receptor which plays a role in the metabolic
syndrome and its associated cardiac events. The pleiotropic
activity and the various molecular associations of this scavenger
in different cells and tissues have however questioned its potential
as a safe therapeutic target. Different published observations have
Table 1. Inhibition of ppTG in the plasma at four hours
following the olive oil gavage following administration of
50 mg/kg of active (AP5055, AP5258) or inactive (AP5156)
analogues.
Plasma postprandial TG (mM) at 4 h
Vehicle 2.8±0.6
AP5156 2.6±0.6
AP5055 1.7±0.8
AP5258 1.7±0.6
doi:10.1371/journal.pone.0037633.t001
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beneficial due to redundant mechanisms or potential toxicity.
The present study shows that it is possible to identify small
molecules that can block the CD36 binding and uptake functions
and that such antagonism can reduce atherosclerosis, postpran-
dial hypertriglyceridemia and be beneficial for type II diabetes.
Particularly, elevated postprandial hypertriglyceridemia is a
metabolic parameter which is now recognized to be strongly
associated with cardiovascular events and is independent of
traditional cardiovascular risk factors [49]. Thus, CD36 might
represent an attractive therapeutic target.
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